A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML).

Trial Profile

A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML).

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Bortezomib (Primary) ; Cytarabine; Etoposide; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Aug 2013 Planned end date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 20 Aug 2013 Planned number of patients changed from 24 to 34 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top